Meta2312 schreef op 28 december 2021 11:15:
Pharming Group (NASDAQ:PHAR) Downgraded by Zacks Investment Research to Hold
December 26, 2021 ETF Daily News Team
Zacks Investment Research downgraded shares of Pharming Group (NASDAQ:PHAR) from a buy rating to a hold rating in a research note published on Saturday morning, Zacks.com reports.
According to Zacks, “Pharming Group N.V. is a commercial stage biopharmaceutical company. It engages in developing protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs. The company’s product portfolio includes C1INH. Pharming Group N.V. is based in Leiden, The Netherlands. “
Shares of PHAR stock opened at $8.75 on Friday. Pharming Group has a 12 month low of $7.58 and a 12 month high of $16.04. The company has a current ratio of 5.18, a quick ratio of 4.65 and a debt-to-equity ratio of 0.73. The stock has a 50-day moving average price of $8.77 and a 200 day moving average price of $10.04.
A hedge fund recently raised its stake in Pharming Group stock. Morgan Stanley grew its position in shares of Pharming Group (NASDAQ:PHAR) by 5,208.3% during the second quarter, according to its most recent filing with the SEC. The firm owned 2,548 shares of the company’s stock after acquiring an additional 2,500 shares during the period. Morgan Stanley’s holdings in Pharming Group were worth $29,000 at the end of the most recent quarter. 0.31% of the stock is currently owned by hedge funds and other institutional investors.
About Pharming Group
Pharming Group N.V., a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema.
etfdailynews.com/news/pharming-group-...